key: cord-0734849-dcmt92em authors: Sanchez-Montalva, A.; Selares-Nadal, J.; Espinosa-Pereiro, J.; Fernandez-Hidalgo, N.; Perez-Hoyos, S.; Salvador, F.; Dura-Miralles, X.; Miarons, M.; Anton, A.; Eremiev, S.; Sempere-Gonzalez, A.; Bosch-Nicolau, P.; Monforte-Pallares, A.; Augustin, S.; Sampol, J.; Guillen-del-Castillo, A.; Almirante, B. title: Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study. date: 2020-05-12 journal: nan DOI: 10.1101/2020.05.07.20094599 sha: 1b6e9ee648a6ffc0297d06e73d3dea87897764f9 doc_id: 734849 cord_uid: dcmt92em Background: Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID19) despite the scarcity of evidence. Methods: We report preliminary results from the Vall dHebron prospective cohort study at Vall dHebron University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed infection with the severe acute respiratory syndrome coronavirus2 (SARSCoV2) and who were treated with tocilizumab until March 25th. The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others. Results: 82 patients with COVID19 received at least one dose of tocilizumab. The mean (SD) age was 59.1 (19.8) years, 63% were male, 22% were of non Spanish ancestry, and the median (IQR) ageadjusted Charlson index at baseline was 3 (1 to 4) points. Respiratory failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median time from symptom onset to ARDS development was 8 (5 to 11) days. The median time from symptom onset to the first dose of tocilizumab was 9 (7 to 11) days. Mortality at 7 days was 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3 to 8.5 (age adjusted hazard ratio for mortality 2.1; 95% CI, 0.8 to 5.8) if tocilizumab was administered after the onset of ARDS. Conclusion: Time from lung injury onset to tocilizumab administration may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data from clinical trials becomes available. Results: 82 patients with COVID-19 received at least one dose of tocilizumab. The mean 151 (± SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and 152 the median (IQR) age-adjusted Charlson index at baseline was 3 (1-4) points. Respiratory 153 failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median 154 time from symptom onset to ARDS development was 8 (5-11) days. The median time from 155 symptom onset to the first dose of tocilizumab was 9 (7-11) days. Mortality at 7 days was 156 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3 to 8.5 (age-adjusted hazard ratio for INTRODUCTION: 164 Coronavirus disease 2019 (COVID-19) is a novel illness caused by severe acute respiratory 165 syndrome coronavirus-2 (SARS-CoV-2). It was first reported in December 2019 in Hubei 166 province, China. 1 Since then, SARS-CoV-2 has rapidly spread worldwide. 167 According to the World Health Organization (WHO), as of April 13 th , 2020, there has been 168 1773084 laboratory-confirmed cases and 111652 deaths. 2 The case fatality rate, estimated 169 between 2.3% and 3.3%, is highly age and underlying conditions dependent. 3, 4 Death is 170 mainly due to respiratory failure caused by an acute respiratory distress syndrome (ARDS). As the physiopathology behind lung injury is progressively elucidated, several therapies 172 have been proposed on the basis of pre-clinical studies and the previous experience with the 173 severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and the Middle East In COVID-19, an excessive immune response inducing disproportionate release of cytokine 178 and hyperinflammation has been proposed as cause for the lung damage mimicking a 179 secondary haemophagocytic lymphohistiocytosis. 12 Host-directed therapies have immune-180 modulating properties with higher precision than steroids and other immune-modulating 181 therapies. 13 Tocilizumab is a humanized monoclonal antibody that inhibits interleukin-6 182 (IL-6) receptor with a well-known safety profile approved for the treatment of rheumatoid 183 arthritis and, since 2017, also approved for the treatment of chimeric antigen receptor 184 (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS). 14,15 It 185 has been used with promising results in small retrospective cohort studies of SARS-CoV-2 186 infected patients in China. 9, 16 The efficacy of other host-directed therapies targeting 187 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020 . . https://doi.org/10.1101 /2020 hyperinflammation is being assessed under randomized clinical trial conditions for severe 188 SARS-CoV-2 infected patients. 17, 18 189 However, a proper characterization of the subset of patients who will benefit most from 190 host-directed therapies and defining the precise timing for host-directed therapies 191 administration has not yet been performed and is critical to allocate limited drug stocks and 192 reduce COVID-19 associated mortality. We aim to describe the characteristics of CoV-2 infected patients treated with tocilizumab and define poor outcome risk factors. 194 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. additional treatment in patients with the following criteria: 1) respiratory failure defined as 208 a ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2 ratio) of <300, 209 a ratio of arterial oxygen saturation measured by pulse oximetry to fraction of inspired 210 oxygen (SpO2/FiO2 ratio) of <315 or pO2 <60mmHg or oxygen saturation measured by 211 pulse oximetry less than 90% when breathing room air or rapidly progressive clinical 212 worsening according to treating physician and 2) interleukin-6 (IL-6) levels >40pg/mL 213 (reference 0-4.3pg/mL) or a D-dimer levels > 1500 ng/mL. Two weight bands were 214 considered for tocilizumab dosing. Patients over 75kg received 600mg, otherwise 400mg 215 was the preferred dose. A second dose was considered in patients with a poor early 216 response. Patients with liver enzymes 5 times over the upper limit of normality or 217 concomitant severe bacterial infection were not eligible for tocilizumab treatment. 218 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020 . . https://doi.org/10.1101 /2020 Data sources 219 Data were collected retrospectively from the medical charts of the patients from the 13 th of 220 March, 2020 to the 18 th of March, 2020, when the protocol was submitted to the 221 institutional review board, and prospectively thereafter. Inclusion and follow-up are still 222 ongoing. The cut-off data for inclusion in this sub-study was March 25 th , 2020. All patients 223 included were followed directly (admitted to medical or intensive care unit wards) for at 224 least 7 days. including C-reactive protein, fibrinogen, ferritin and IL-6. All radiographs were reviewed 240 by the investigators and computed tomography (CT) scans were recorded according to the 241 radiology department reports. The severity of the COVID-19 was measured with the 242 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The primary simple endpoint was defined as death at 7 days after first dose of tocilizumab. Secondary outcomes were admission to Intensive Care Unit (ICU), acute Respiratory 262 Distress Syndrome (ARDS) and respiratory insufficiency progression. We also assessed 263 acute myocardial infarction, septic shock, acute kidney injury and secondary infections. Berlin criteria for the ARDS were adapted, as many of the patients did not have an 265 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. . https://doi.org/10.1101/2020.05.07.20094599 doi: medRxiv preprint review board code number: PR(AG)183/2020). Patients were asked for an oral consent. The 290 institutional review board granted an informed consent waiver if patients were unable to 291 give oral consent. The manuscript was prepared according to the STROBE guidelines 292 recommendations. All the authors reviewed the manuscript and vouch for the accuracy and 293 completeness of the data and for the adherence of the study to the protocol. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. Thirty-three (40.3%) patients were former or active tobacco smokers. Coexisting conditions 313 were as follows: 32 (39.0%) had hypertension, 19 (23.5%) had lung diseases (2 (2.4%) 314 asthma, 6 (7.3%) chronic obstructive pulmonary disease among others), 17 (20.7%) had 315 obesity, 16 (19.5%) had diabetes mellitus, 11 (13.6%) had chronic kidney disease, 5 (6.1%) 316 a history of cardiac failure, 1 (1.2%) had cirrhosis. Ten (12.5%) patients were 317 immunosuppressed because of different conditions. Seventy-seven (95.1%) patients had a 318 Barthel scale index of 100 points previous to hospital admission. Table 1 shows 319 demographic and clinical characteristics at baseline. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. Table 3 . 340 Oxygen supplementation and secondary outcomes. 341 Table 4 shows oxygen saturation, oxygen supplementation and ventilation support. On 342 admission, mean FiO2 oxygen supplementation was 0.36 (±0.26) and mean oxygen 343 saturation was 94% (±4.39). Regarding oxygen supplementation devices on admission, 34 344 (41.5%) patients were on oxygen supplementation: two (5.8%) patients were on nasal 345 cannulas, 22 (64.7%) were using face masks, 9 (26.5%) patients were using high oxygen 346 supplementation devices and 1 (2.9%) patient required endotracheal intubation with 347 mechanical ventilation. Over time, SpO2/FiO2 ratio deteriorated from a median (IQR) of 348 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. Table 5 . from symptom onset to tocilizumab administration was 9.0 (6.0-11.0) and from admission 368 to tocilizumab administration was 2.0 (1.0-3.0)). Other treatments include cytokine 369 hemoadsorption therapy in 2 (2.4%) patients in ICU. Main outcome and mortality risk factors 371 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. were hospitalized in ICU, 9 (11.0%) were hospitalized in medical wards, and 3 (3.7%) had 374 been transferred to another institution. In the univariate analysis age, age-adjusted Charlson 375 comorbidity index, medical history of active or former solid cancer, hypertension, history 376 of heart failure, chronic kidney disease and worse age-adjusted Charlson index at baseline 377 were associated with increased risk of mortality (Table 7 ). By 7-day follow-up, the 378 mortality rate was 4.0% per person-day (95% confidence interval [CI], 2.4% to 6.2%) by 379 Kaplan-Meier analysis. Mortality was more frequent in patients receiving tocilizumab once 380 ARDS was present (hazard ratio for mortality 3.3; 95% CI, 1.3 to 8.5; age-adjusted hazard 381 ratio for mortality 2.1; 95% CI, 0.8 to 5.8) (Figure 1 ) or respiratory failure was present 382 (hazard ratio for mortality 3.13; 95% CI, 1.3 to 7.8; age-adjusted hazard ratio for mortality (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. . https://doi.org/10.1101/2020.05.07.20094599 doi: medRxiv preprint associated with higher mortality in the univariate analysis. Antihypertensive agents, such as (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. . https://doi.org/10. 1101 /2020 As in other infections and inflammation-driven diseases, timely initiation of precise therapy 454 is the mainstay of patient management and directly affects mortality and morbidity. Our 455 study showed that patients receiving prompt treatment with tocilizumab before lung injury 456 is established have less 7-day mortality, a benefit that may be sustained in the long-term. 33 The safety profile of tocilizumab has been extensively studied in clinical trials with patients (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. . This preliminary exploratory study has several limitations. First, there is no control group 477 and the minimum follow up period was 7 days. Therefore, at this point it is not possible to 478 evaluate the differences between patients receiving tocilizumab or not and, consequently, it 479 is not possible to evaluate solidly what is the overall benefit of administering this drug. COVID-19 should consider our preliminary data in their design. All our patients were 497 treated with a combination of antiviral drugs whose efficacy is yet to be demonstrated. Host-directed therapies in the absence of antiviral drugs needs further investigation. 499 500 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. Group (ECOG) performance scale range from 0 (fully active) to 4 (completely disabled). ∫ 603 The Charlson risk index score ranges from 0 to 37 with higher scores indicating a higher 604 risk of death. ¶ Sequential Organ Failure Assessment (SOFA) score ranges from 0 to 24 605 with higher ranges indicating a higher risk or morbidity; individuals with a score of 15 or 606 more have a mortality rate of 90%. Its calculation is missing in two patients. § Community 607 acquired pneumonia severity index assessing Confusion, Urea, Respiratory rate, Blood 608 pressure and age over 65 years (CURB-65) ranges from 0 to 5 depending on the number 609 of risk factors present in the same patient. 610 GFR: glomerular filtration rate. 611 ¬ One patient had insterstitial lung disease and pulmonary hypertension and another 612 patient had obtructive sleep apnea syndrome and lung restrictive disease. 613 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (±SD) . Rounding has been applied to percentages. Total may no be 100 because of rounding. †Total number of patients varies among variables and follow up as mortality increases. SpO2/FiO2 ratio: arterial oxygen saturation measured by pulse oximetry to fraction of inspired oxygen Former daily alcohol consumption -2 (9.1) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020. Days from respiratory insufficiency to tocilizumab 0 (0 -1) 1 (0 -2) 0.055 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020 . . https://doi.org/10.1101 /2020 administration, median (IQR) Days from ARDS to tocilizumab administration, median (IQR) 0 (-1 -0) 0 (0 -1) 0.132 *Plus-minus values are means (±SD). Rounding has been applied to percentages. Total may no be 100 because of rounding. †Includes high flow oxygen delivery systems, high flow nasal cannula, non-invasive mechanical ventilation or invasive ventilation ARDS: acute respiratory distress syndrome. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 12, 2020 . . https://doi.org/10.1101 /2020 Prothrombin time Urea, median (IQR) -mg/dl 43 Glomerular filtrate, mean -CKD-EPI Aspartate aminotransferase > 40 U/litre 42 (53.9%) 25 (61%) 30 (66.7%) Alanine aminotransferase Alanine aminotransferase > 40 U/litre 28 Alkaline phosphatase Gamma-glutamyl transferase, mean